Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma
Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma
About this item
Full title
Author / Creator
Publisher
Washington, DC: Endocrine Society
Journal title
Language
English
Formats
Publication information
Publisher
Washington, DC: Endocrine Society
Subjects
More information
Scope and Contents
Contents
Abstract
Context
Although mitotane is the only approved drug for the treatment of adrenocortical carcinoma (ACC), data on monotherapy in advanced disease are still scarce.
Objective
To assess the efficacy of mitotane in advanced ACC in a contemporary setting and to identify predictive factors.
Design and Setting
Multicenter cohort...
Alternative Titles
Full title
Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2003047401
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2003047401
Other Identifiers
ISSN
0021-972X
E-ISSN
1945-7197
DOI
10.1210/jc.2017-02591
